LARYNG-O-JET KIT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LARYNG-O-JET KIT (LARYNG-O-JET KIT).
Lidocaine, a local anesthetic, stabilizes neuronal membranes by inhibiting sodium ion channels, blocking initiation and conduction of nerve impulses. Epinephrine causes vasoconstriction via alpha-1 adrenergic receptor activation, reducing systemic absorption of lidocaine and prolonging local effect.
| Metabolism | Lidocaine: primarily hepatic via CYP1A2 and CYP3A4. Epinephrine: metabolized by catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO). |
| Excretion | Renal excretion of unchanged drug accounts for approximately 70% of elimination, with 30% undergoing hepatic metabolism and biliary/fecal elimination. |
| Half-life | Terminal elimination half-life is 1.5–2 hours (mean 1.8 h), necessitating frequent dosing for sustained effect. |
| Protein binding | Approximately 55% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Volume of distribution is 6–8 L/kg, indicating extensive tissue distribution beyond plasma volume. |
| Bioavailability | Topical mucosal bioavailability is 80–100% due to direct application; negligible systemic bioavailability via oral route (<5%). |
| Onset of Action | Local application: onset within 2–5 minutes due to direct mucosal absorption. |
| Duration of Action | Clinical effect lasts 30–60 minutes after topical application, influenced by vascularity of site and drug concentration. |
| Molecular Weight | Lidocaine hydrochloride: 288.8 Da; Epinephrine hydrochloride: 333.8 Da |
Topical administration via laryngeal spray: 1-2 sprays (10-20 mg) to the larynx and pharynx, repeated as needed up to every 1-2 hours, not to exceed 8 sprays per 24 hours.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No dose adjustment required for hepatic impairment. |
| Pediatric use | Not recommended for use in pediatric patients due to risk of laryngospasm and systemic toxicity. |
| Geriatric use | Dose selection should be cautious, usually starting at the low end of the dosing range, due to increased sensitivity and risk of adverse effects. |
| 1st trimester | Lidocaine crosses the placenta but is not associated with major birth defects at usual doses. Epinephrine may reduce uteroplacental blood flow; use only if clearly needed. |
| 2nd trimester | Lidocaine crosses the placenta; no increased risk of fetal harm with standard doses. Epinephrine should be used with caution due to potential vasoconstriction. |
| 3rd trimester | Lidocaine may cause fetal bradycardia or CNS effects at high doses. Epinephrine can decrease uterine blood flow; avoid near term unless essential. |
Clinical note
Comprehensive clinical and safety monograph for LARYNG-O-JET KIT (LARYNG-O-JET KIT).
| Placental transfer | Lidocaine readily crosses the placenta; epinephrine crosses in limited amounts. Both are considered low-risk at therapeutic doses. |
| Breastfeeding | Lidocaine is excreted into breast milk in small amounts, unlikely to cause adverse effects in the infant. Epinephrine is poorly absorbed orally. Generally compatible with breastfeeding. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
Hypersensitivity to lidocaine, epinephrine, or any componentSevere hypotensionShock or history of adverse reaction to local anestheticsConcurrent use of MAOIs or tricyclic antidepressants (risk of severe hypertension with epinephrine)Intravenous or regional use for dental procedures (not indicated)Porcine allergy (LARYNG-O-JET contains porcine gelatin)
| Precautions | Risk of systemic toxicity if excessive doses or rapid absorption occur, Use with caution in patients with hepatic impairment, cardiac disease, or hypotension, Epinephrine component may cause hypertension, tachycardia, or arrhythmias, Avoid injection into inflamed or infected tissues |
| Food/Dietary | Avoid all oral intake (food, drink, gum, candy) for at least 60 minutes post-procedure to prevent aspiration. No known direct food-drug interactions, but local anesthetics may impair taste and swallowing reflex temporarily. |
Loading safety data…
| Lactation Rating | L2 |
| Teratogenic Risk | Lidocaine hydrochloride (20 mg/mL) and epinephrine (0.01 mg/mL) combination. Lidocaine crosses placenta; fetal:baternal ratio ~0.5-0.7. No major teratogenicity reported at standard doses; high systemic doses may cause fetal acidosis. Epinephrine may reduce uteroplacental blood flow; risk of fetal hypoxia at high doses. FDA Pregnancy Category B (lidocaine), Category C (epinephrine). First trimester: avoid high doses; second/third trimester: use only if clearly needed. |
| Fetal Monitoring | Monitor maternal vital signs (HR, BP, O2 sat), ECG for lidocaine toxicity (prolonged PR, QRS, CNS effects). Fetal heart rate monitoring if prolonged use or high dose. Observe for signs of local anesthetic systemic toxicity (LAST). |
| Fertility Effects | No known negative impact on fertility in animal studies; limited human data. Lidocaine and epinephrine not associated with impaired fertility at standard doses. |
| Clinical Pearls | LARYNG-O-JET KIT is a topical anesthetic spray (20% benzocaine) for oropharyngeal anesthesia. Onset: 15-30 seconds; duration: 5-10 minutes. Max dose: 200 mg benzocaine per procedure (10 sprays). Avoid in patients with methemoglobin reductase deficiency, G6PD deficiency, or known hypersensitivity to ester-type anesthetics. Use in pediatrics: only if >2 years, max 1 spray per 10 kg body weight. Monitor for methemoglobinemia: cyanosis unresponsive to oxygen, chocolate-brown blood. Have methylene blue (1% solution, 1-2 mg/kg IV) available. Avoid in patients with severe hepatic impairment. Do not spray directly on pharynx in supine patients to prevent aspiration. |
| Patient Advice | Do not eat or drink for at least 1 hour after use to prevent choking due to numbing of throat. · Inform your doctor if you have a history of methemoglobinemia, G6PD deficiency, or allergy to benzocaine or other ester anesthetics. · Do not exceed the number of sprays recommended by your doctor. Overuse can lead to serious side effects. · Seek immediate help if you experience bluish skin, lips, or nail beds, difficulty breathing, headache, or dizziness. · Keep out of reach of children. This medication is for professional use only in a clinical setting. |